Abbott, Shareholders Agree To Settle Depakote Marketing Suit
By Jamie Santo (March 7, 2014, 8:11 PM EST) -- Abbott Laboratories shareholders asked an Illinois federal judge on Thursday to bless a settlement resolving a derivative suit that alleged Abbott's directors cost the company $1.6 billion because they did nothing to stop the marketing of its anti-seizure drug Depakote for off-label uses.
The settlement — reached between the lead shareholder plaintiff, Abbott and its board — would dismiss the derivative suit with prejudice in exchange for the company agreeing to beef up its corporate oversight procedures, according to documents filed with the U.S. District Court for the Northern District of Illinois.
Lead plaintiff Jacksonville Police & Fire Pension Fund seeks...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!